Skip to main content
Premium Trial:

Request an Annual Quote

Modest Amusement Indeed

In the September/October issue of Technology Review, Duke's Misha Angrist says that the authorities in California and New York were "wrongheaded and arrogant" to insist that the services offered by personal genomics companies need to have a physician gatekeeper. True, the tests haven't been validated, and Angrist says that will take years. "This is where we are in the era of personal genomics: some modest amusement, a few interesting tidbits, a bit of useful information, but mostly the promise of much better things to come," writes Angrist.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.